Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives

Thrombosis Research

Volumn 134, Issue 5, 2014, Pages 1032-1037

  Tchaikovski, S N ^a,b   Thomassen, M C L G D ^a   Costa, S D ^c   Bremme, K ^b,d   Rosing, J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c Division of Obstetrics and Gynaecology   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Drospirenone containing oral contraceptives; Protein S; TFPI; Tthrombin generation

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; DROSPIRENONE PLUS ETHINYLESTRADIOL; PROTEIN C; PROTEIN S; PROTHROMBIN; SEX HORMONE BINDING GLOBULIN; TISSUE FACTOR PATHWAY INHIBITOR; ANDROSTANE DERIVATIVE; DROSPIRENONE; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; ORAL CONTRACEPTIVE AGENT; THROMBIN;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLICULAR PHASE; HEMOSTASIS; HUMAN; LUTEAL PHASE; MALE; ORAL CONTRACEPTIVE USE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; DRUG EFFECTS; MENSTRUAL CYCLE; METABOLISM; YOUNG ADULT;

ADULT; ANDROSTENES; BLOOD COAGULATION; CONTRACEPTIVES, ORAL; FEMALE; HEMOSTASIS; HUMANS; LIPOPROTEINS; MENSTRUAL CYCLE; PROTEIN S; THROMBIN; YOUNG ADULT;

EID: 84927584499     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.09.008     Document Type: Article

References (35)

1. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002; 22:201-10.
2. Jick H, Jick SS, Gurewich V, Myers M.W., Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346:1589-93.
3. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339:b2921.
4. Muhn P, Fuhrmann U, Fritzemeier K.H., Krattenmacher R., Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995; 761:311-35.
5. Lidegaard O, Nielsen LH, Skovlund C.W., Skjeldestad FE, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progesto-gens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343:d6423.
6. In brief: FDA warning about drospirenone in oral contraceptives. Med Lett Drugs Ther 2012; 54:33.
7. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembo-lism. Thromb Res 2010; 126:5-11.
8. Tans G, Curvers J, Middeldorp S., Thomassen MC, Meijers JC, Prins MH, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84:15-21.
9. Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, Tans G, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84:4-8.
10. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke J.P., Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503-6.
11. Tans G, van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-70.
12. Rosing J, Middeldorp S, Curvers J., Christella M, Thomassen LG, Nicolaes G.A., et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354:2036-40.
13. Tchaikovski SN, Thomassen MC, Costa S.D., Peeters LL, Rosing J. Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia. Thromb Haemost 2011; 106:914-21.
14. Oslakovic S, Zadro R. Comparison of the Impact of Four Generations of Progestins on Hemostatic Variables. Clin Appl Thromb Hemost 2014; 20:448-55.
15. Kluft C, Endrikat J, Mulder S.M., Gerlinger C., Heithecker R. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception 2006; 73:336-43.
16. Machado RB, deMelo NR, Maia Jr H, Cruz AM. Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles. Contraception 2010; 81:102-6.
17. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, he-mostatic parameters and carbohydrate metabolism. Contraception 2005; 71:409-16.
18. van Vliet HA, Bertina RM, Dahm A.E., Rosendaal FR, Rosing J, Sandset PM, et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost 2008; 6:346-51.
19. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A 2006; 103:3106-11.
20. Dielis AW, Castoldi E, Spronk H.M., van Oerle R, Hamulyak K, Ten Cate H, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6:125-31.
21. Koedam JA, Meijers JC, Sixma J.J., Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82:1236-43.
22. Rosing J, Bakker HM, Thomassen M.C., Hemker HC, Tans G. Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem 1993; 268: 21130-6.
23. Schiffman S, Theodor I, Rapaport SI. Separation from Russell's viper venom of one fraction reacting with factor X and another reacting with factor V. Biochemistry 1969; 8:1397-405.
24. Maurissen LFA. Characterisation of anticoagulant functions of protein S. PhD Thesis. Print and Copy Service Moons, Hasselt. Maastricht University, Maastricht, the Netherlands; 2009.
25. Maurissen LF, Castoldi E, Simioni P., Rosing J, Hackeng TM. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost 2010; 8: 750-8.
26. van Rooijen M, Silveira A, Thomassen S., Odeberg J, Hamsten A, Rosing J., et al. APC resistance during the normal menstrual cycle. Thromb Haemost 2007; 98:1246-51.
27. Nicolaes GA, Thomassen MC, van Oerle R, Hamulyak K, Hemker H.C., Tans G., et al. A prothrombinase-based assay for detection of resistance to activated protein C. Thromb Haemost 1996; 76:404-10.
28. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33:4-15.
29. Tchaikovski SN, van Vliet HA, Thomassen MC, Bertina RM, Rosendaal FR, Sandset P.M., et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007; 98:1350-6.
30. Duchemin J, Pan-Petesch B, Arnaud B., Blouch MT, Abgrall JF. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost 2008; 99:767-73.
31. Broze Jr GJ, Lange GW, Duffin K.L., MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1994; 5:551-9.
32. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006; 208:327-39.
33. Donahue BS, Gailani D, Mast AE. Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass. J Thromb Haemost 2006; 4:1011-6.
34. Koh SC, Prasad RN, Fong YF. Hemostatic status and fibrinolytic response potential at differentphases of the menstrual cycle. Clin Appl Thromb Hemost 2005; 11:295-301.
35. Chaireti R, Gustafsson KM, Bystrom B, Bremme K., Lindahl TL. Endogenous thrombin potential is higher during the luteal phase than during the follicular phase of a normal menstrual cycle. Hum Reprod 2013; 28:1846-52.